ADC Therapeutics (ADCT) - Long-Term Debt to Capital

Corporate emblem and logo of ADC Therapeutics (ADCT)

ADC Therapeutics is attracting top biologists to develop targeted oncology treatments, providing them with a robust resource base and stock options. The company's price chart reflects dynamics driven by a dependence on Swiss developments and global trials, which have been complicated by logistical hurdles. The indicator stands at 0.00, while management is currently optimizing sales and combating capital burn amid fierce competition.

ADC Therapeutics Corp - ADCT Long-Term Debt to Capital (period 07/04/2022 - 10/31/2026)

Analytical breakdowns for ADC Therapeutics

- stock value and consensus price forecast:
Stock Quotes ADC Therapeutics S.A.|ADCT - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization ADC Therapeutics SA|ADCT - Total Company Value
- company book value details:
Equity per Share ADC Therapeutics|ADCT - Book Capitalization|Market Cap to Net Assets Ratio adctherapeutics.com|ADCT - Company Total Assets
- company liabilities and liquidity data:
Debt to Capital ADC Therapeutics|ADCT - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital adctherapeutics.com|ADCT - Company Total Debt|Debt to Net Assets Ratio ADC Therapeutics SA|ADCT - Company Long-Term Debts|Company Short-Term Debt ADC Therapeutics|Quick Liquidity adctherapeutics.com
- financial results and valuation multiples details:
ADCT - Company Net Income
General company analysis:ADC Therapeutics S.A. - ADCT
Original product of adctherapeutics.com

The stability of the biomedical sector amid geopolitical neutrality allows ADC Therapeutics (ADCT) to strategically plan its financing, which is reflected in the long-term debt-to-equity ratio. This ratio measures the proportion of borrowed capital with a maturity exceeding one year, determining financial stability and management discipline, as clearly demonstrated by the long-term debt-to-equity coefficient.

Key competitors

Long-Term Debt to Equity Ratio TG Therapeutics Inc (TGTX)|Long-Term Debt to Capital ACLX|Long-Term Debt to Capital Disc Medicine Pharma (IRON)|Long-Term Debt to Equity Syndax Pharmaceuticals SNDX|KURA: Long-Term Debt to Capital Ratio|Foghorn - Long-Term Debt to Capital|Vor Biopharma, Inc. (VOR) - Long-Term Debt to Equity Ratio|NKTX: Long-Term Debt to Capital|Long-Term Liabilities to Capital Coeptis Therapeutics, Inc. (COEP)|Long-Term Debt to Equity Actinium Pharmaceuticals|ESLA: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio CASI (CASI Pharmaceuticals)|MRKR (markertherapeutics.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital INAB (IN8bio, Inc)|Eterna Therapeutics, Inc. - Long-Term Debt to Equity|GTBP - Long-Term Debt to Equity|APTO: Long-Term Debt to Equity|Bio-Path Holdings, Inc. (BPTH) - Long-Term Debt to Equity|Long-Term Liabilities to Capital MEI Pharma Inc (MEIP)|Long-Term Debt to Equity Vincerx Pharma Inc.